Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Perspective on Current Alternatives in Nanotoxicology Research

Perspective on Current Alternatives in Nanotoxicology Research APPLIED IN VITRO TOXICOLOGY GUEST EDITORIAL Volume 5, Number 3, 2019 ª Mary Ann Liebert, Inc. DOI: 10.1089/aivt.2019.29020.jrr Perspective on Current Alternatives in Nanotoxicology Research Todd A. Stueckle, PhD, and Jenny R. Roberts, PhD he evolution of nanotechnology proceeds at an mations in different biological mediums (e.g., biocorona, sol- T unprecedented rate due to major investments in research ubilization, etc.), modeling and use of appropriate deposited and development from public and private sectors. Incorpora- dose and dose metrics, appropriate in vitro model for both tion of engineered nanomaterials (ENMs) into novel or re- exposure and response that aligns with in vivo adverse out- placement technologies has impacted a diverse number of come, and increased development and use of standardized as- 6–8 industrial, commercial, consumer, and health-care services says for read-across purposes. and products. Use of ENMs in many industries has, however, Current advances in machine learning, in silico, in vitro, raised concerns with all routes of exposure (dermal, oral, in- and tissue model techniques have placed predictive modeling halation, and parenteral) in occupational, consumer, and en- of the in vivo response with an integrative alternative tiered vironmental settings. Given the sheer number, diversity, and toxicity testing strategy a potential http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied In Vitro Toxicology Mary Ann Liebert

Perspective on Current Alternatives in Nanotoxicology Research

Perspective on Current Alternatives in Nanotoxicology Research

Applied In Vitro Toxicology , Volume 5 (3): 3 – Sep 1, 2019

Abstract

APPLIED IN VITRO TOXICOLOGY GUEST EDITORIAL Volume 5, Number 3, 2019 ª Mary Ann Liebert, Inc. DOI: 10.1089/aivt.2019.29020.jrr Perspective on Current Alternatives in Nanotoxicology Research Todd A. Stueckle, PhD, and Jenny R. Roberts, PhD he evolution of nanotechnology proceeds at an mations in different biological mediums (e.g., biocorona, sol- T unprecedented rate due to major investments in research ubilization, etc.), modeling and use of appropriate deposited and development from public and private sectors. Incorpora- dose and dose metrics, appropriate in vitro model for both tion of engineered nanomaterials (ENMs) into novel or re- exposure and response that aligns with in vivo adverse out- placement technologies has impacted a diverse number of come, and increased development and use of standardized as- 6–8 industrial, commercial, consumer, and health-care services says for read-across purposes. and products. Use of ENMs in many industries has, however, Current advances in machine learning, in silico, in vitro, raised concerns with all routes of exposure (dermal, oral, in- and tissue model techniques have placed predictive modeling halation, and parenteral) in occupational, consumer, and en- of the in vivo response with an integrative alternative tiered vironmental settings. Given the sheer number, diversity, and toxicity testing strategy a potential

Loading next page...
 
/lp/mary-ann-liebert/perspective-on-current-alternatives-in-nanotoxicology-research-MYjZKt76oT
Publisher
Mary Ann Liebert
Copyright
Copyright 2019, Mary Ann Liebert, Inc., publishers
ISSN
2332-1512
eISSN
2332-1539
DOI
10.1089/aivt.2019.29020.jrr
Publisher site
See Article on Publisher Site

Abstract

APPLIED IN VITRO TOXICOLOGY GUEST EDITORIAL Volume 5, Number 3, 2019 ª Mary Ann Liebert, Inc. DOI: 10.1089/aivt.2019.29020.jrr Perspective on Current Alternatives in Nanotoxicology Research Todd A. Stueckle, PhD, and Jenny R. Roberts, PhD he evolution of nanotechnology proceeds at an mations in different biological mediums (e.g., biocorona, sol- T unprecedented rate due to major investments in research ubilization, etc.), modeling and use of appropriate deposited and development from public and private sectors. Incorpora- dose and dose metrics, appropriate in vitro model for both tion of engineered nanomaterials (ENMs) into novel or re- exposure and response that aligns with in vivo adverse out- placement technologies has impacted a diverse number of come, and increased development and use of standardized as- 6–8 industrial, commercial, consumer, and health-care services says for read-across purposes. and products. Use of ENMs in many industries has, however, Current advances in machine learning, in silico, in vitro, raised concerns with all routes of exposure (dermal, oral, in- and tissue model techniques have placed predictive modeling halation, and parenteral) in occupational, consumer, and en- of the in vivo response with an integrative alternative tiered vironmental settings. Given the sheer number, diversity, and toxicity testing strategy a potential

Journal

Applied In Vitro ToxicologyMary Ann Liebert

Published: Sep 1, 2019

There are no references for this article.